Oral Paricalcitol in Stage 3 - 5 Chronic Kidney Disease

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Chronic Kidney Disease
Interventions
DRUG

paricalcitol

oral paricalcitol capsule 1 microgram once daily if iPTH \<500pg/mL or 2 microgram once daily if iPTH \>=500pg/mL. Thereafter, dose titration in 1 microgram decrement will be done based on safety reasons (that is, for low PTH or high calcium and phosphorus level). The duration of treatment will be for 1 year.

Trial Locations (2)

0000

Queen Mary Hospital, Hong Kong

University of Hong Kong, Queen Mary Hospital, Hong Kong

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

The University of Hong Kong

OTHER

NCT00796679 - Oral Paricalcitol in Stage 3 - 5 Chronic Kidney Disease | Biotech Hunter | Biotech Hunter